24 completed, 11 unknown, 4 recruiting, 3 withdrawn. 47 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 47 | Completed 24, Unknown 11, Recruiting 4, Withdrawn 3, Not yet recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Terminated 1 |
Follow dolutegravir: new trials by email Literature Review of dolutegravir trials Research Report on dolutegravir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | 40 | 2026-10-05 | 2026-10-06 |
| Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) - HIV-1-infection | Phase 4 | Recruiting | Fundación Huésped | 210 | 2026-09-10 | 2026-09-18 |
| Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG) - HIV, HIV-1 | Phase 4 | Recruiting | UBATEC | 50 | 2025-07-31 | 2025-09-12 |
| Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults. Dolutegravir (DTG), Darunavir/Cobicistat (FDC) - HIV, Insomnia | Phase 4 | Unknown | Instituto Mexicano del Seguro Social | 140 | 2025-06-19 | 2025-06-26 |
| Evaluation of Switch to Dolutegravir/Lamivudine (DTG/3TC) From Current Suppressive Antiretroviral Therapy in People Living With HIV (PLWH) Receiving Opioid Agonist Therapy (OAT) DOVATO - HIV-1-infection, Opioid Use Disorder | Phase 4 | Not yet recruiting | Saskatchewan Health Authority - Regina Area | 40 | 2024-09-30 | 2024-08-30 |
| Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial TLD - Tenofovir Disoproxil Fumarate / Lamivudine / Dolutegravir - HIV Prevention | Phase 4 | Recruiting | University of Witwatersrand, South Africa | 100 | 2024-06-01 | 2026-06-09 |
| B-free Multistage Trial DOR/DTG/3TC - HIV, Drug Resistance | Phase 4 | Enrolling by invitation | Insel Gruppe AG, University Hospital Bern | 210 | 2023-11-13 | 2024-12-04 |
| Doravirine Dose Optimisation in Pregnancy Doravirine, Dolutegravir - HIV | Phase 4 | Recruiting | University of Liverpool | 76 | 2023-10-10 | 2026-02-19 |
| Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine. - HIV Infections, Fatty Liver Disease | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 63 | 2023-05-26 | 2025-07-18 |
| Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity Dolutegravir 50 MG plus lamivudine 300 MG; Dolutegravir/lamivudine (50 MG/300 MG) - Acquired Immunodeficiency Syndrome | Phase 4 | Unknown | Shanghai Public Health Clinical Center | 100 | 2022-08-01 | 2022-08-09 |
| Drug Interactions Between Dolutegravir and Escalating Doses of Rifampicin Dolutegravir - Hiv, Tuberculosis | Phase 4 | Completed | Helen Reynolds | 36 | 2021-11-18 | 2024-08-13 |
| Investigating the Interaction Between Two Long-acting Reversible Methods of Contraception and Dolutegravir, a Treatment for HIV Dolutegravir, Levonorgestrel implant, Depo medroxyprogesterone acetate injection - Human Immunodeficiency Virus, Contraception | Phase 4 | Unknown | Botswana Harvard AIDS Institute Partnership | 140 | 2021-10-21 | 2023-07-27 |
| Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Dolutegravir/Lamivudine - Human Immunodeficiency Virus | Phase 4 | Unknown | Saint Michael's Medical Center | 40 | 2021-09-26 | 2023-10-11 |
| Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB Dolutegravir 50 MG, Dolutegravir 10 MG - Tuberculosis, Hiv | Phase 4 | Unknown | University of KwaZulu | 20 | 2021-08-19 | 2024-02-01 |
| DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: Dolutegravir/Lamivudine as a single pill, Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill. - HIV-1-infection | Phase 4 | Completed | Fundacion SEIMC-GESIDA | 554 | 2021-07-14 | 2025-07-18 |
| Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 Intervention Arm: dolutegravir/lamivudine, Comparator ARM: TDF/XTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine) - HIV-1-infection | Phase 4 | Completed | Fundación Huésped | 265 | 2021-05-17 | 2025-07-30 |
| Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] - Hiv, HIV Infections | Phase 4 | Unknown | Thomas Benfield | 126 | 2021-02-02 | 2021-05-27 |
| Inflammation and Co-Infections in D²EFT NRTIs, Darunavir, Ritonavir - HIV-infection/Aids, Human Herpesvirus 4 Infections | Phase 4 | Withdrawn | Kirby Institute | 2021-02-01 | 2020-11-10 | |
| Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals Artemether-lumefantrine - HIV Coinfection, Malaria | Phase 4 | Unknown | Makerere University | 888 | 2021-01-18 | 2023-01-06 |
| Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test Lamivudine 300 MG, Emtricitabine / Tenofovir Disoproxil Pill - Hiv, HIV-1-infection | Phase 4 | Completed | Fundacion IDEAA | 244 | 2020-11-17 | 2024-02-21 |
Showing 20 of 47. Sign in to see all of them.
Acquired Immunodeficiency Syndrome (16) · HIV Infections (9) · Body Weight Changes (2) · Tuberculosis (2) · Anxiety Disorders (1) · Bone Diseases, Metabolic (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Coinfection (1) · Cytomegalovirus Infections (1) · Depression (1) · Epstein-Barr Virus Infections (1) · HIV-Associated Lipodystrophy Syndrome (1) · Infections (1) · Inflammation (1)
Fundación Huésped (3) · Kirby Institute (3) · St Stephens Aids Trust (3) · Fundacion SEIMC-GESIDA (2) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (2) · Thomas Benfield (2) · University of Witwatersrand, South Africa (2) · Andrew Carr (1) · Augusta University (1) · Botswana Harvard AIDS Institute Partnership (1) · Charlotte-Paige Rolle, MD (1) · Cristina Mussini (1) · Emory University (1) · Erasmus Medical Center (1) · Fundacion Clinic per a la Recerca Biomédica (1)
Spain (8) · Argentina (7) · South Africa (7) · United States (7) · Brazil (4) · Thailand (3) · Uganda (3) · United Kingdom (3) · Australia (2) · Denmark (2) · India (2) · Italy (2) · Malaysia (2) · Zimbabwe (2) · Belgium (1)
Saye Khoo (2) · Angela DM Kashuba, BScPhmPharmD (1) · Bart Rijnders, MD, PhD (1) · Cecile Lahiri, MD (1) · Charlotte-Paige Rolle, MD (1) · Chelsea Morroni, PhD MBChB (1) · Esteban Martinez, MD (1) · Ezequiel Cordova, MD (1) · Flavia Kiweewa Matovu, MBChB, MSc (1) · Francois WD Venter, PhD (1) · Gail Matthews, MBBCh (1) · Gail Matthews, MD (1) · Gilles Wandeler, Prof (1)
PMID 23824675, PMID 26856824, PMID 28537061, PMID 29107562, PMID 29617822, PMID 29643011, PMID 29912307, PMID 30005011, PMID 31033629, PMID 35411401, PMID 36259527, PMID 37207617, PMID 37342923, PMID 37604629, PMID 37908359, PMID 38023553, PMID 38652564, PMID 38721980, PMID 38788744, PMID 39578038, PMID 39826566, PMID 40023169, PMID 40354181, PMID 40489982, PMID 40874763, PMID 41083105, PMID 41779383, PMID 42162408
2017 (1), 2018 (1), K23AI124913 (1), R01AI122319 (1)